Hyaluronic acid (HA) has been widely explored in cancer drug delivery due to its biocompatibility, biodegradability and excellent cargo properties.
Recently, HA-based formulations have gained renewed interest thanks to the HA involvement in many CD44-overexpressing tumors, offering potential for active targeting, tumor microenvironment modulation, and immune response regulation.
